12 stories found
A fierce global battle is underway among European, American, and Chinese pharmaceutical companies to dominate the obesity treatment market. Novo Nordisk CEO Doustdar believes that no single player will monopolize this rapidly growing sector.
Mike Doustdar, CEO of Novo Nordisk, stated that employees seeking easy work will not find it at the company. He emphasized that working for Novo Nordisk requires accepting longer workdays, tougher competition, and clearer performance demands.
Block (formerly Square) is heading into its earnings report with significant expectations from investors. The company needs to deliver on its Q2 guidance to meet these high hopes.
Novo Nordisk CEO Mike Doustdar told the Financial Times that the pharmaceutical industry is only "scratching the surface" of the market, explaining why the company made a deal with Trump last year.
A guide highlights the most cringeworthy summer greetings from top executives at major Danish companies including Danske Bank, Carlsberg, Novo Nordisk, DSV, and Mærsk.
Mike Doustdar, CEO of Novo Nordisk, marks one year in his position, with reports highlighting how his upbringing without parents contributed to his resilience.
Mike Doustdar, a top executive at Novo Nordisk, has announced plans to invest billions in new drug development, aiming to secure the pharmaceutical giant's future. He acknowledged that the company might face failures but is determined to leave Novo Nordisk in a stronger position.
Investors are closely watching Novo Nordisk's stock, which has faced significant declines, as they await a crucial financial figure that could reverse the company's headwinds, with analysts questioning CEO Mike Doustdar's ability to boost earnings despite price cuts.
Novo Nordisk's stock experienced a surprising decline despite the company reporting strong earnings, with analysts pointing to several factors, including details on page 20 of its financial report, as potential reasons for investor skepticism. This unexpected market reaction has prompted re-evaluation from investors and analysts.
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the…
Novo Nordisk's chief, Mike Doustdar, emphasized injecting risk-taking into the Ozempic maker, expressing openness to large deals and a strategy to reduce reliance on weight-loss drugs.
Doustdar tror, at Cagrisema bliver det bedste på markedet. Nye data viser højere vægttab med et andet middel.